

Financial ResultsReference No **CA-100824-36866**

Company Name : **TMC LIFE SCIENCES BERHAD**
 Stock Name : **TMCLIFE**
 Date Announced : **25/08/2010**
 Financial Year End : **31/12/2010**
 Quarter : **2**
 Quarterly report for the financial period ended : **30/06/2010**
 The figures : **have not been audited**

Converted attachment :

Please attach the full Quarterly Report here:

[@TMC Life Sciences 2nd QR.pdf](#)

Remark:

- DEFAULT CURRENCY
- OTHER CURRENCY

Currency : Malaysian Ringgit (MYR)

SUMMARY OF KEY FINANCIAL INFORMATION
30/06/2010

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
	30/06/2010 \$\$'000	30/06/2009 \$\$'000	30/06/2010 \$\$'000	30/06/2009 \$\$'000
1Revenue	14,281	11,812	26,649	21,990
2Profit/(loss) before tax	-2,693	-2,169	-5,288	-5,014
3Profit/(loss) for the period	-2,776	-2,217	-5,432	-5,046
4Profit/(loss) attributable to ordinary equity holders of the parent	-2,724	-2,090	-5,340	-4,843
5Basic earnings/(loss) per share (Subunit)	-0.45	-0.35	-0.89	-0.81

6Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
--	------	------	------	------

	AS AT END OF CURRENT QUARTER	AS AT PRECEDING FINANCIAL YEAR END
7Net assets per share attributable to ordinary equity holders of the parent (\$\$)	0.1621	0.1720

Remarks :

Definition of Subunit:

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit. Example for the subunit as follows:

Country	Base Unit	Subunit
Malaysia	Ringgit	Sen
United States	Dollar	Cent
United Kingdom	Pound	Pence

© 2012, Bursa Malaysia Berhad. All Rights Reserved.



TMC LIFE SCIENCES BHD
Company no. 624409-A
(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT
FOR THE SECOND QUARTER ENDED 30 JUNE 2010**

Contact

No 11 Jalan Teknologi
Taman Sains Selangor 1
PJU 5, Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111
Fax: +603 6287 1212

TMC LIFE SCIENCES BHD

Company no. 624409-A

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE
SECOND QUARTER ENDED 30 JUNE 2010**

CONDENSED CONSOLIDATED INCOME STATEMENT

	Note	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
		CURRENT YEAR QUARTER 30 Jun 2010 (UNAUDITED) RM	PRECEDING YEAR CORRESPONDING QUARTER 30 Jun 2009 (UNAUDITED) RM	CURRENT YEAR TO-DATE 30 Jun 2010 (UNAUDITED) RM	PRECEDING YEAR CORRESPONDING QUARTER 30 Jun 2009 (UNAUDITED) RM
Revenue		14,281,380	11,812,037	26,648,924	21,990,222
Operating expenses		(14,210,077)	(11,536,387)	(26,519,879)	(22,439,573)
Profit/(Loss) from operations		71,303	275,650	129,045	(449,351)
Amortisation & depreciation		(2,078,431)	(2,200,728)	(4,113,047)	(3,909,171)
Finance costs		(669,563)	(339,551)	(1,306,002)	(770,361)
Interest income		11,224	95,894	29,794	115,332
Share of loss of associate		(27,769)	-	(28,262)	-
Loss before taxation		(2,693,235)	(2,168,735)	(5,288,471)	(5,013,551)
Taxation	B5	(82,874)	(48,269)	(143,436)	(32,924)
Loss after taxation		(2,776,109)	(2,217,004)	(5,431,907)	(5,046,475)
ATTRIBUTABLE TO:					
Equity holders of the Company		(2,724,405)	(2,090,292)	(5,340,373)	(4,842,911)
Minority interests		(51,704)	(126,712)	(91,534)	(203,564)
		(2,776,109)	(2,217,004)	(5,431,907)	(5,046,475)
(Loss) / Earnings per share (sen)					
- Basic	B14	(0.45)	(0.35)	(0.89)	(0.81)
- Diluted		N/A	N/A	N/A	N/A

Note : N/A denotes Not Applicable

The condensed consolidated income statement should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BHD

Company no. 624409-A

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE
SECOND QUARTER ENDED 30 JUNE 2010

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	CURRENT YEAR QUARTER 30 Jun 2010 (UNAUDITED) RM	PRECEDING YEAR CORRESPONDING QUARTER 30 Jun 2009 (UNAUDITED) RM	CURRENT YEAR TO-DATE 30 Jun 2010 (UNAUDITED) RM	PRECEDING YEAR CORRESPONDING QUARTER 30 Jun 2009 (UNAUDITED) RM
Loss after taxation	(2,776,109)	(2,217,004)	(5,431,907)	(5,046,475)
<i>Other comprehensive income/(loss)</i>				
Currency translation differences	660	(8,068)	2,408	12,177
Total comprehensive loss for the period	(2,775,449)	(2,225,072)	(5,429,499)	(5,034,298)
Total comprehensive loss attributable to:				
Equity holders of the Company	(2,723,745)	(2,098,360)	(5,337,965)	(4,830,734)
Minority interests	(51,704)	(126,712)	(91,534)	(203,564)
	(2,775,449)	(2,225,072)	(5,429,499)	(5,034,298)

The condensed consolidated statement of comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BHD

Company no. 624409-A

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE
SECOND QUARTER ENDED 30 JUNE 2010****CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

	Note	AS AT 30 June 2010 (UNAUDITED) RM	AS AT 31 December 2009 (RESTATED) RM
ASSETS			
Non-Current Assets			
Property, plant and equipment		135,453,158	135,213,059
Long term trade receivables		1,472,251	-
Goodwill		3,331,190	3,331,190
Intangible assets		9,794,168	12,528,472
Investment in associate		337,859	216,121
		<u>150,388,626</u>	<u>151,288,842</u>
Current Assets			
Inventories		3,851,870	3,627,209
Trade receivables		5,217,772	6,358,070
Other receivables, deposits and prepayments		4,111,012	4,703,402
Other investment		-	2,510,682
Cash and cash equivalents		4,363,932	5,263,851
		<u>17,544,586</u>	<u>22,463,214</u>
TOTAL ASSETS		<u>167,933,212</u>	<u>173,752,056</u>
EQUITY AND LIABILITIES			
Equity Attributable To Equity Holders Of The Company			
Share capital		60,177,975	60,177,975
Share premium		21,751,724	21,751,724
Exchange rate reserve		(809)	(3,217)
Retained profits		15,584,120	21,495,335
Total Equity		<u>97,513,010</u>	<u>103,421,817</u>
Minority interests		22,494	114,028
Total Equity Attributable To Equity Holders Of The Company		<u>97,535,504</u>	<u>103,535,845</u>
Non-Current Liabilities			
Term loans		39,131,365	40,318,838
Hire purchase		359,801	413,109
Deferred taxation		3,229,167	3,229,167
		<u>42,720,333</u>	<u>43,961,114</u>
Current Liabilities			
Trade payables		2,569,062	5,412,385
Other payables		12,558,637	10,380,197
Term loans		7,486,455	7,678,563
Hire purchase		112,604	112,604
Bank overdraft		4,943,606	2,671,290
Tax payable		7,011	58
		<u>27,677,375</u>	<u>26,255,097</u>
TOTAL LIABILITIES		<u>70,397,708</u>	<u>70,216,211</u>
TOTAL EQUITY AND LIABILITIES		<u>167,933,212</u>	<u>173,752,056</u>
NET ASSETS PER TEN SEN ORDINARY SHARE (RM)		<u>0.1621</u>	<u>0.1720</u>

The condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BHD

Company no. 624409-A

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE
SECOND QUARTER ENDED 30 JUNE 2010**

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share Capital RM	Share Premium RM	Foreign Exchange Translation Reserve RM	Distributable Retained Profits RM	Total RM	Minority Interests RM	Total Equity RM
At 1 January 2010	60,177,975	21,751,724	(3,217)	21,495,335	103,421,817	114,028	103,535,845
Effect of adopting FRS 139	-	-	-	(570,842)	(570,842)	-	(570,842)
As at 1 January 2010, restated	60,177,975	21,751,724	(3,217)	20,924,493	102,850,975	114,028	102,965,003
Total comprehensive loss for the year	-	-	2,408	(5,340,373)	(5,337,965)	(91,534)	(5,429,499)
At 30 June 2010	60,177,975	21,751,724	(809)	15,584,120	97,513,010	22,494	97,535,504
At 1 January 2009	60,177,975	21,751,724	(23,462)	32,103,833	114,010,070	7,656	114,017,726
Total comprehensive income/(loss) for the year	-	-	20,245	(8,803,159)	(8,782,914)	57,492	(8,725,422)
Shares subscribed by minority shareholders	-	-	-	-	-	48,880	48,880
Dividends paid	-	-	-	(1,805,339)	(1,805,339)	-	(1,805,339)
At 31 December 2009	60,177,975	21,751,724	(3,217)	21,495,335	103,421,817	114,028	103,535,845

The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BHD

Company no. 624409-A

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE
SECOND QUARTER ENDED 30 JUNE 2010****CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**

	PERIOD ENDED 30 June 2010 RM (UNAUDITED)	PRECEDING YEAR ENDED 31 December 2009 RM (AUDITED)
Cash flows from operating activities		
Loss before taxation	(5,288,471)	(8,797,995)
Adjustments for		
Non-cash items	4,520,640	8,808,790
Gain on disposal of property, plant and equipment	(7,620)	(172,968)
Share of loss/(profit) in associated company	28,262	(736)
Interest paid	1,306,002	1,744,741
Interest income	(29,794)	(151,638)
Operating profit before changes in working capital	<u>529,019</u>	<u>1,430,194</u>
Changes in working capital:		
Net change in current assets	1,508,027	16,872,273
Net change in current liabilities	(664,883)	(3,193,516)
Cash generated from operations	<u>1,372,163</u>	<u>15,108,951</u>
Interest paid	(1,306,002)	(1,744,741)
Interest received	29,794	151,638
Income tax paid	(289,205)	(653,743)
Net cash (used in)/generated from operating activities	<u>(193,250)</u>	<u>12,862,105</u>
Cash flows from investing activities		
Acquisition of property, plant and equipment	(3,991,360)	(44,344,123)
Nurse sponsorship incurred, net of receipts	-	(1,033,877)
Proceeds from disposal of property, plant and equipment	25,650	335,300
Investment in associate company	(93,476)	(215,385)
Issuance of subsidiary's ordinary shares	-	48,880
Other investment redeemed/(purchased)	2,510,682	(2,498,713)
Net cash used in investing activities	<u>(1,548,504)</u>	<u>(47,707,918)</u>
Cash flows from financing activities		
Dividends paid	-	(1,805,339)
(Repayment) / drawdown of term loan	(1,379,581)	17,997,401
Repayment of hire purchase	(53,308)	(74,287)
Net cash (used in)/ generated from financing activities	<u>(1,432,889)</u>	<u>16,117,775</u>
Net decrease in cash and cash equivalents	(3,174,643)	(18,728,038)
Cash and cash equivalents at beginning of financial period/year	2,592,561	21,302,176
Effects of exchange rate changes on cash and bank balances	2,408	18,423
Cash and cash equivalents at end of financial period/year	<u>(579,674)</u>	<u>2,592,561</u>
NOTES TO CASH FLOW STATEMENT		
Cash and cash equivalents comprise:		
Cash and bank balances	4,363,932	5,263,851
Bank overdraft	(4,943,606)	(2,671,290)
Total cash and cash equivalents	<u>(579,674)</u>	<u>2,592,561</u>

The condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE SECOND QUARTER ENDED 30 JUNE 2010**

A EXPLANATORY NOTES PURSUANT TO FINANCIAL REPORTING STANDARD ("FRS")

A1 BASIS OF PREPARATION

The interim financial statements have been prepared in accordance with the requirements of Financial Reporting Standards (FRS) 134 "Interim Financial Reporting" and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad for the Main Board.

The interim financial statements should be read in conjunction with the audited financial statements of the Group for the year ended 31 December 2009. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2009.

A2 CHANGES IN ACCOUNTING POLICIES

The significant accounting policies adopted are consistent with those of the audited financial statements for the financial year ended 31 December 2009, except for the adoption of the following new Financial Reporting Standards (FRSs) and IC Interpretations with effect from 1 January 2010:

FRS 4	Insurance Contracts
FRS 7	Financial Instruments: Disclosures
FRS 8	Operating Segments
FRS 101	Presentation of Financial Statements (Revised)
FRS 123	Borrowing Costs (Revised)
FRS 132	Financial Instruments: Presentation (Revised)
FRS 139	Financial Instruments: Recognition and Measurement
Amendment to FRS 1	First-time Adoption of Financial Reporting Standard
Amendment to FRS 2	Share-based Payment –Vesting conditions and Cancellations
Amendment to FRS 7	Financial Instruments: Disclosures
Amendment to FRS 8	Operating Segments
Amendment to FRS 107	Statement of Cash Flows
Amendment to FRS 108	Accounting Policies, Changes in Accounting Estimates and Errors
Amendment to FRS 110	Events after the Reporting Period
Amendment to FRS 116	Property, Plant & Equipment
Amendment to FRS 117	Leases
Amendment to FRS 118	Revenue
Amendment to FRS 119	Employee Benefits
Amendment to FRS 127	Consolidated and Separate Financial Statements
Amendment to FRS 132	Financial Instruments: Presentation
Amendment to FRS 134	Interim Financial Reporting
Amendment to FRS 136	Impairment of Assets
Amendment to FRS 138	Intangible Assets
Amendment to FRS 139	Financial Instruments: Recognition and Measurement
IC Interpretation 9	Reassessment of Embedded Derivatives
IC Interpretation 10	Interim Financial Reporting and Impairment

A2 CHANGES IN ACCOUNTING POLICIES (CONT'D)

The principal effects of the changes in presentation, changes in methods of computation and in accounting policies resulting from the adoption of the new and revised FRSs, IC Interpretations and Amendments are set out below:

i) FRS 8: Operating Segments

FRS 8 requires segment information to be presented on a similar basis to that used for internal reporting purposes. A review of the Group's reportable segment concluded that the Group is primarily engaged in one operating segment namely, the healthcare sector. This conclusion is consistent with the financial information regularly reviewed by the Group's chief operating decision maker who makes decisions on the allocation of resources and assesses the performance of the Group. This standard does not have any impact on the financial position and results of the Group.

ii) FRS 101 : Presentation of Financial Statements

The FRS 101 introduces the statement of comprehensive income: presenting all items of income and expense recognized in the income statement, together with all the other items of recognized income and expense, either in one single statement, or in two linked statement. In addition, a statement of financial position is required at the beginning of the earliest comparative period following a change in accounting policy, the correction of an error or the reclassification of items in the financial statement. Comparative information, with exception of the requirements under FRS 139, have been re-presented to be in conformity with the revised standard. The FRS did not have any impact on the financial position and results of the Group.

iii) FRS 117 : Leases

The amendments requires entity with existing leases of land and building to reassess the classification of land as finance or operating lease. Following the amendments, the Group has reclassified the existing leasehold land to property, plant and equipment, with no effect on reported profit or equity. However, as a result of the adoption of the amendments, comparative balances as at 31 December 2009 has been restated as follows:

	As previously reported	Effect of adopting amendments to FRS117	As restated
	RM	RM	RM
Property, plant and equipment	116,429,729	18,783,330	135,213,059
Prepaid land lease payments	18,783,330	(18,783,330)	-

iv) FRS 139 : Financial Instruments : Recognition and Measurement

The FRS 139 establishes principles for recognizing and measuring financial assets, financial liabilities and some contracts to buy and sell non-financial items. This FRS did not have any significant impact on the financial position and results of the Group

Impact on opening balance

In accordance with the transitional provisions of FRS139, the changes are applied prospectively and the comparative as at 31 December 2009 are not restated. Instead, the changes have been accounted for by restating the following opening balances in the Statement of Financial Position as at 1 January 2010.

iv) FRS 139 : Financial Instruments : Recognition and Measurement (cont'd)

	Previously stated	Effect of FRS139	As restated
	RM	RM	RM
Assets			
Long term receivables	-	1,472,251	1,472,251
Trade receivables	6,358,070	(2,043,092)	4,314,978
Equity			
Retained earnings	21,495,335	(570,842)	20,924,493

A3 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

There were no audit qualifications in the annual financial statements of the Company and its subsidiaries for the financial year ended 31 December 2009.

A4 SEASONALITY OR CYCLICALITY OF OPERATIONS

The business of the Group is not significantly affected by any seasonal or cyclical factors.

A5 UNUSUAL ITEMS

During the current quarter under review, there were no items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A6 CHANGE IN ESTIMATES

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial period under review.

A7 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial period under review.

A8 VALUATION OF PROPERTY, PLANT AND EQUIPMENT

There was no revaluation on any of the Group's property, plant and equipment during the current financial period under review.

A9 DIVIDENDS PAID

No dividend was paid in the current financial period ended 30 June 2010.

A10 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and currently is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital. The Group also provides fertility and gynecological services, stem cell banking and therapy, and research and development in life sciences.

A11 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There were no material events subsequent to 31 December 2009 and up to the date of this report.

A12 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current financial period under review other than disclosed below.

On 1 June 2010, the Company subscribed for 150,000 ordinary shares of RM1.00 each in its associated company, Academy of Nursing (M) Sdn. Bhd. by way of Rights Issue at an issue price of RM1.00 each on the basis of four (4) new ordinary shares for every one (1) existing ordinary share held, at a total consideration of RM150,000 and renounced its rights on the remaining 10,000 ordinary shares of RM1.00 each.

On 18 June 2010, the Company disposed of 15 (fifteen) ordinary shares of RM1.00 each representing 15% of the issued and paid-up capital in its wholly-owned subsidiary, Tropicana Medical Centre (Penang) Sdn. Bhd. for a total consideration of RM735,176 to its wholly-owned subsidiary, TMC Women's Specialist Holdings Sdn. Bhd.

A13 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

The Company has provided corporate guarantees to licensed financial institutions for banking facilities and suppliers amounting to RM60.125 million and RM3.0 million respectively. The guarantees were granted for the benefit of the Company's wholly-owned subsidiaries. The banking facilities are primarily for financing the construction and equipping of the Group's flagship hospital. Arising from this, the Company is contingently liable for the amount utilized by its subsidiary companies of approximately RM52.03 million as at 30 June 2010.

A14 CAPITAL COMMITMENTS

Capital expenditures not provided for in the interim financial report as at 30 June 2010 are as follows:

	RM '000
Approved and contracted for	5,471
Approved but not contracted for	211
	<u>5,683</u>

A15 SIGNIFICANT RELATED PARTY TRANSACTIONS

The directors are of the opinion that the transactions below have been entered into in the normal course of business and have been established on the terms and conditions that are not materially different from those obtainable in transactions with unrelated parties.

The Company and/or its subsidiaries	Transacting Parties	Relationship	Nature of transaction	Current Quarter Ended 30 Jun 10 RM	Cumulative Quarter Ended 30 Jun 10 RM
TMC Women's Specialist Holdings Sdn Bhd	Dato' Dr Lee Soon Soo	Director and substantial shareholder of the Company	Rental of premise	3,600	7,200
IVF Technologies Sdn bhd	Dato' Dr Lee Soon Soo	Director and substantial shareholder of the Company	Rental of signage space	1,200	2,400

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES")

B1 REVIEW OF PERFORMANCE

For the 6 months ended 30 June 2010 ("1H10"), group revenue grew 21.19% to RM26.65 million compared to RM21.99 million achieved in the corresponding period in the previous year. The improvement was mainly due to the increased revenues from the Group's flagship multi disciplinary tertiary hospital, as a result of the hospital now operating with more comprehensive services during the period under review than were offered in 1H09. In addition, promotional activities of the hospital during the financial year ended 31 December 2009 helped in the market awareness of the hospital.

However the period under review saw the Group registering a loss after taxation and minority interests of RM5.34 million as compared to a loss after tax and minority interests of RM4.84 million recorded in the corresponding period in the previous year. The increase in the loss was due to several factors such as higher depreciation and finance costs during the period under review. Operating expenses also increased in tandem with expanded facilities and services offered at the hospital.

Review of performance	Current quarter (RM'mil)	Preceding year corresponding quarter (RM'mil)	Changes %	Current period (RM'mil)	Preceding year corresponding period (RM'mil)	Changes %
Revenue	14.28	11.81	20.91%	26.65	21.99	21.19%
(Loss)/Profit after taxation and minority interest	(2.72)	(2.09)	30.14%	(5.34)	(4.84)	10.33%

B2 COMPARISON WITH PRECEDING QUARTER'S RESULTS

The Group recorded a revenue and loss before taxation of RM14.28 million and RM2.69 million respectively for the current quarter as compared to a revenue of RM12.37 million and loss before taxation of RM2.60 million in the preceding quarter. The decreased financial performance was due to higher finance costs and other operating expenses.

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 31 DECEMBER 2010

The Board is positive that the Group's revenue base will continue to increase in FY2010, spurred by the increased number of specialist doctors and support personnel at the flagship hospital, as well as ongoing promotional activities of the hospital's advanced facilities and services. In addition, the Group's other fertility centres, wellness program, and stem cell services will continue to contribute to the Group's revenue. The Board will endeavour to improve the operational efficiency of the Group.

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

Not applicable.

B5 TAXATION

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	QUARTER ENDED	QUARTER ENDED	PERIOD ENDED	PERIOD ENDED
	30 Jun 2010	30 Jun 2009	30 Jun 2010	30 Jun 2009
Malaysian income tax:				
- current taxation	(82,874)	(48,269)	(143,436)	(32,924)
- prior year taxation	-	-	-	-
- deferred taxation	-	-	-	-
Total	(82,874)	(48,269)	(143,436)	(32,924)

The effective tax rate was higher than the statutory income tax rate in Malaysia due to the losses of certain subsidiaries that were not available for set off against taxable profits of other subsidiaries and certain expenses which were not deductible for tax purposes.

B6 PROFIT ON SALE OF UNQUOTED INVESTMENTS AND/OR PROPERTIES

There were no sale of unquoted investments and/or properties during the current financial period under review.

B7 QUOTED SECURITIES

There were no purchases or disposals of quoted securities during the current financial period under review.

B8 SIGNIFICANT EVENT

There was no significant event in the quarter under review.

B9 STATUS OF CORPORATE PROPOSAL

There were no corporate proposals in this quarter except the following:

On 18 September 2008, the Company entered into a Memorandum of Understanding with Berjaya Corporation Berhad and Viet Ha Corporation to establish a formal relationship in order to jointly carry out activities relating to the design, construction, furnishing, equipping and operating of a hospital in or near Hanoi, Vietnam.

Further to the announcement made on 18 September 2008, the parties to the Memorandum of Understanding (MOU) have mutually agreed to extend the duration of the MOU for a further period of twelve (12) months from 17 September 2009 until 17 September 2010.

There is no material development since the last announcement.

B10 BORROWINGS

The Group's borrowings as at 30 June 2010 are as follows:-

	Long Term (RM million)	Short Term (RM million)	Total (RM million)
Secured	39.49	12.54	52.03
Unsecured	-	-	-
Total	39.49	12.54	52.03

B11 OFF BALANCE SHEET FINANCIAL INSTRUMENTS

There were no off balance sheet financial instruments as at the date of this report.

B12 MATERIAL LITIGATION

There were no material litigations as at the date of this report.

B13 DIVIDENDS

The Board does not recommend the payment of any dividend for the current financial period under review.

B14 EARNINGS PER SHARE

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	QUARTER ENDED	QUARTER ENDED	PERIOD ENDED	PERIOD ENDED
Basic earnings per share (EPS)	30 Jun 2010	30 Jun 2009	30 Jun 2010	30 Jun 2009
Net (loss) / profit attributable to shareholders	(2,724,405)	(2,090,292)	(5,340,373)	(4,842,911)
Weighted average number of ordinary shares in issue ('000)	601,780	601,780	601,780	601,780
(LPS)/EPS (sen) - Basic	(0.45)	(0.35)	(0.89)	(0.81)
- Diluted	N/A	N/A	N/A	N/A